Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply
On August 4, Odyssey Therapeutics (NASDAQ:ODTX) reported its second-quarter financial results and gave investors a fresh look at where its lead autoimmune drug candidate stands.
Odyssey Therapeutics Inc. (ODTX)
Market is closed
Sector: Healthcare
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 1,388,889 | $25,000,002.00 | 3,690,146 | 2026-05-11 | Filing | |
| $18.00 | 1,111,111 | $19,999,998.00 | 3,333,516 | 2026-05-08 | Filing | |
| $18.00 | 200,000 | $3,600,000.00 | 1,014,851 | 2026-05-11 | Filing | |
| $18.00 | 133,333 | $2,399,994.00 | 574,314 | 2026-05-11 | Filing | |
| $18.00 | 222,222 | $3,999,996.00 | 1,831,383 | 2026-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 438 | $7,884.00 | 814,851 | 2026-05-11 | Filing | |
| $18.00 | 277 | $4,986.00 | 440,981 | 2026-05-11 | Filing | |
| $18.00 | 1,065 | $19,170.00 | 1,609,161 | 2026-05-11 | Filing |
News See All
Hedge Fund Resource Center